c-Fos proto-oncoprotein is a short-lived transcription factor degraded by the proteasome in vivo. Its mutated forms expressed by the mouse osteosarcomatogenic retroviruses, FBJ-MSV and FBR-MSV, are stabilized two-and threefold, respectively. To elucidate the mechanisms underlying v-Fos FBJ and v-Fos FBR protein stabilization, we conducted a genetic analysis in which the half-lives and the sensitivities to various cell-permeable protease inhibitors of a variety of cellular and viral protein mutants were measured. Our data showed that the decreased degradation of v-Fos FBJ and v-Fos FBR is not simply explained by the deletion of a c-Fos destabilizing C-terminal domain. Rather, it involves a complex balance between opposing destabilizing and stabilizing mutations which are distinct and which include virallyintroduced peptide motifs in both cases. The mutations in viral Fos proteins conferred both total insensitivity to proteasomal degradation and sensitivity to another proteolytic system not naturally operating on c-Fos, explaining the limited stabilization of the two proteins. This observation is consistent with the idea that FBR-MSV and FBJ-MSV expression machineries have evolved to ensure controlled protein levels. Importantly, our data illustrate that the degradation of unstable proteins does not necessarily involve the proteasome and provide support to the notion that highly related proteins can be broken down by dierent proteolytic systems in living cells. Oncogene (2001) 20, 942 ± 950.
Introduction
The c-fos proto-oncogene codes for a transcription factor (c-Fos), a component of the AP-1 transcription complex that is a key regulator of biological processes such as cell proliferation, dierentiation, apoptosis and response to stress (Piechaczyk and Blanchard, 1994) . It is expressed at low or undetectable levels in most cell types but it can be rapidly and transiently induced by many stimuli (Curran, 1988; Piechaczyk and Blanchard, 1994) . Accumulation of c-Fos outside its physiological windows of expression is sucient for cell transformation (Miao and Curran, 1994) and induction of benign bone tumors in transgenic mice (Ruther et al., 1987 (Ruther et al., , 1989 Schmidt et al., 1995) .
c-fos gene has been transduced in mutated forms by two mouse retroviruses, FBJ-MSV and FBR-MSV (Van Beveren et al., 1983) , inducing aggressive and lethal osteosarcomas (Curran, 1988) . Both v-Fos proteins show a higher intrinsic oncogenic potential than c-Fos, that of v-Fos FBR being the strongest in vitro and in vivo (Curran, 1988; Jotte and Holt, 1996; Piechaczyk and Blanchard, 1994) . Furthermore, the mutations present in the coding and non-coding regions permit the viral genes to evade the exquisitely controlled transcriptional and posttranscriptional mechanisms operating on c-fos (Piechaczyk and Blanchard, 1994) . This leads to constitutive expression of viral Fos proteins, which is crucial for their oncogenic activity. Of particular interest, mutated viral proteins show a reduced turnover and therefore accumulate to higher levels and manifest a stronger oncogenic eect. Elucidating the molecular basis responsible for this dierential stability is thus essential for a complete understanding of the mechanisms of oncogenic activation of Fos genes expressed by FBJ-MSV and FBR-MSV.
Most, if not all, unstable cellular proteins studied thus far are physiologically degraded by the proteasome, which is the major non-lysosomal cellular protease (DeMartino and Slaughter, 1999) . Most often, but not always (Verma and Deshaies, 2000) , the addressing to the proteasome requires conjugation of multiubiquitin chains to protein substrates . The proteasome has been shown to play a crucial role in c-Fos destruction in mouse and human ®broblasts during the G 0 -to-S phase transition (Salvat et al., 1998) and in a lymphoma cell line undergoing apoptosis (He et al., 1998) . Lysosomes and calpains have also been suggested to contribute to cFos breakdown (Aniento et al., 1996; Carillo et al., 1994; Hirai et al., 1991; Salvat et al., 1999; Watt and Molloy, 1993) . However, this contribution is, at best, minor and could aect c-Fos destruction only within the cytoplasm. Whether c-Fos ubiquitinylation is required for proteasomal degradation has not yet been unambiguously shown. Thus, c-Fos can be ubiquitinylated by puri®ed or semi-puri®ed ubiquitinylation enzymes in vitro (Hermida-Matsumoto et al., 1996; Stancovski et al., 1995) and is slightly stabilized in one mutant cell line (hamster E36-ts20 cell line) thermosensitive for the ubiquitin pathway when cultured at the restrictive temperature (Stancovski et al., 1995) . However, it is not stabilized (Salvat et al., 1998) in another thermosensitive cell mutant (mouse A31N-ts20 cells) (Salvat et al., 2000) and c-Fos-ubiquitin conjugates have, thus far, not been described in vivo.
Here, we report the comparison of the half-lives and sensitivities to a panel of cell-permeant protease inhibitors of a series of wild-type and mutant c-and vFos proteins. We show that the two-and threefold longer half-lives of v-Fos FBJ and v-Fos FBR do not just result from the loss of a C-terminal c-Fos destabilizing element which would have simply entailed reduced proteasomal degradation rate. Rather, our genetic analysis points to complex interplays between destabilizing and stabilizing mutations which are distinct in the two v-Fos proteins. It also indicates that the mutations, while bringing about full insensitivity to proteasomal degradation, also confer sensitivity to another protease not naturally operating on c-Fos and, thereby, limit the accumulation of v-Fos proteins in virus-infected cells. In addition to shedding light on the complex molecular mechanisms of v-Fos protein stabilization, our work also provides an experimental support to the important notion that structurally related proteins are not necessarily degraded via the same pathway.
Results

Cellular and viral Fos protein half-lives
v-Fos FBJ (381 amino acids; Figure 1A ) contains ®ve scattered point mutations and a frameshift that replaces the last 48 amino acids of c-Fos with an unrelated 49 amino acid-long tail (Piechaczyk and Blanchard, 1994) . v-Fos FBR is a 554 amino acid protein ( Figure 1A ), of which (i) 310 are encoded by retrovirus Gag-derived sequences and replace the N-terminal 24 amino acids of c-Fos, (ii) 236 are derived from c-Fos; and (iii) eight are derived from a genomic locus called fox and replace the C-terminal 98 amino acids of cFos. Five point mutations and two in-frame deletions of 13 and 9 amino acids are also scattered throughout the Fos moiety of the molecule. Finally, v-Fos FBR is cotranslationally myristoylated on the Gag N-terminal glycine, which becomes accessible to acylation after removal of the initiator methionine (Resh, 1994) . This modi®cation is quantitative and stable over time and is crucial for the tumorigenic activity of the protein (Abbott and Holt, 1997a,b; Jotte and Holt, 1996; Jotte et al., 1994; Kamata and Holt, 1992; Kamata et al., 1991) .
v-Fos FBJ and v-Fos FBR are more stable than c-Fos . However, the half-lives of the three proteins have never been compared in the same experimental setting. Cos-7 cells were thus transfected in parallel with viral and cellular Fos expression plasmid vectors and protein half-lives were measured in pulse-chase experiments. The mean values of the half-lives measured in four independent experiments were 54+5, 107+9 and 140+6 min for c-Fos, v-Fos FBJ and v-Fos FBR , respectively ( Figure 1B ), indicating that v-Fos FBR is the most stabilized protein. Half-lives of c-and v-Fos proteins in Cos-7 cells being comparable to those observed in murine cells , further experiments were conducted with Cos-7 cells for experimental convenience. We then addressed whether v-Fos proteins are degraded by the proteasome in vivo. Pulse-chase experiments were carried out in the absence or presence of cell-permeable protease inhibitors with dierent inhibition spectra. The chase period was for 8 h, at which point c-Fos was no longer detectable and v-Fos proteins were signi®cantly decreased (Figure 2 ). The inhibitors were: (i) calpain inhibitor II (N-acetyl-LLeucinyl-L-Leucinyl-Methional), which inhibits calpains and several lysosomal cathepsins but not the proteasome; (ii) E64D, an inhibitor of cysteine proteases including calpains and various lysosomal cathepsins but not of the proteasome; (iii) chloroquine, a weak base inhibiting lysosomal enzymes, (iv) MG132 (carbobenzoxyl-L-Leucinyl-L-Leucinyl-L-Leucinal-H), a potent proteasome inhibitor which also inhibits calpains and various lysosomal cathepsins; (v) AAF-CMK (Ala-Ala-Phe-chloromethylketone), an inhibitor of serine proteases of the subtilisin family such as TPPII (Geier et al., 1999) that also inhibits the multicorn protease (Osmulski and Gaczynska, 1998) ; and (vi) Z-VAD-FMK (N-benzyloxycarbonyl-Val-AlaAsp-¯uoromethylketone), a general inhibitor of caspases (Villa et al., 1997) .
MG132, but none of the other inhibitors tested, strongly inhibited c-Fos degradation (Figure 2A Figure  2C ± F). Importantly, viral Fos protein degradation cannot be explained by MG132 depletion because: (i) c-Fos, which is the most unstable protein of the three analysed here and which, in principle, would have been the most sensitive to any leakage in proteasomal inhibition, was fully stabilized for the entire 8 h chase period, (ii) the onset of viral protein decay is visible at the earliest time points of the chase and not at later times as would be expected in case of drug exhaustion (not shown); and (iii) addition of fresh MG132 during the chase did not stabilize v-Fos proteins (not shown). It was important to rule out that another proteolytic system operating on viral proteins, but not on c-Fos, could substitute for the proteasome in degrading viral proteins during the chase period after artifactual activation by MG132. No delay in viral Fos protein disappearance in the presence of MG132 was observed when protein decay rates in the absence and presence of the drug were compared, even at the earliest time points tested (not shown), thus excluding the possible involvement of the proteasome, even in the early period of the chase. Notably, v-Fos FBJ and v-Fos Figure 1A ) which carries a destabilizing element in its last 20 amino acids (Tsurumi et al., 1995) . Indeed, deletion of the last 48 amino acids from c-Fos (construct cFosDC48) led to a twofold increase in protein half-life ( Figure 3A , compare a and b). The fact that MG132 did not stabilize the c-FosDC48 mutant ( Figure 3B , compare a and b), raised the possibility that the mere absence of this domain in the two viral proteins might be sucient for both stabilization and resistance to the proteasome. To test this hypothesis, we studied v-Fos proteins lacking their C-terminal non-Fos domains in pulse-chase experiments performed in the presence or absence of MG132. Deletion of the last 49 amino acids destabilized v-Fos FBJ (construct v-Fos FBJ DC; Figure 3A , compare c and d). Interestingly, pulse-chase experiments in the presence of MG132 showed that the truncated protein was a proteasome substrate ( Figure  3Bd ). This indicates that, in the context of the fulllength v-Fos FBJ molecule, the C terminus of v-Fos Figure 3A ; compare e and f), it did not confer sensitivity to proteasome ( Figure 3B ; compare e and f). This suggests that this motif, although playing a role in the control of the v-Fos FBR degradation rate, is not involved in the resistance to proteasomal degradation. In conclusion, it is not merely the deletion of the Cterminal domain of c-Fos which accounts for the increased stability of v-Fos proteins. Rather, the Cterminal motifs acquired by both viral proteins during retroviral transduction contribute signi®cantly to the stabilization process. Importantly though, the Cterminus of v-Fos FBJ , but not that of v-Fos FBR , plays a role in the resistance to proteasomal degradation, indicating that the determinants controlling resistance to the proteasome are distinct in the two viral proteins. (Abbott and Holt, 1997a,b; Jotte and Holt, 1996; Jotte et al., 1994; Kamata and Holt, 1992; Kamata et al., 1991) , an important issue was to assess its possible role in Gag-mediated stabilization and acquisition of proteasome resistance. The mutant v-Fos FBR G2A, in which the myristoylated glycine was mutated into a non-myristoylable alanine (Kamata et al., 1991) , was as unstable (Figure 4Cd ) as v-Fos FBR DN (Figure 4Ca ). Moreover, this mutant was stabilized in the presence of MG132 (Figure 4Da ), indicating a major contribution for myristoylation in the stabilization and insensitivity of v-Fos FBR to the proteasome. We then assessed whether the myristoylated Gag acted in concert with other mutations to confer resistance to the proteasome. A cooperation between Fox and the myristoylated Gag could already be excluded since removal of Fox from v-Fos FBR (construct v-Fos FBR DC; Figure 3Bf ) did not confer any sensitivity to the proteasome. Interestingly, the replacement of the Fos moiety of v-Fos FBR by the homologous non-mutated region of c-Fos did not In conclusion, the stabilization of v-Fos FBR is not simply determined by the loss of the cFos C-terminal domain but by a complex balance between destabilizing and stabilizing mutations. Stabilization is attributable mainly to the combined eects of the Fox and myristoylated Gag motifs but resistance to the proteasome is primarily determined by the myristoylation of Gag.
Discussion
v-Fos
FBJ and v-Fos FBR escape proteasomal degradation and are sensitive to another proteolytic system not operating on c-Fos
Under conditions of constitutive expression, which are those of FBJ-MSV and FBR-MSV-transduced fos genes, c-Fos degradation is fully inhibited in the presence of MG132, indicating that proteasomal degradation of c-Fos is not restricted to the G 0 -to-S phase transition (Salvat et al., 1998) but can occur during other phases of the cell cycle. In contrast, vFos FBJ and v-Fos FBR are longer-lived and have acquired resistance to the proteasome. Sensitivity of c-Fos to the proteasome in asynchronously growing cells was con®rmed in further experiments using lactacystin, which is a drug showing a narrower speci®city than MG132 for inhibiting the proteasome. However, if often satisfactory when used in short-term experimental settings, this drug is often inactivated in longer experiments by various mechanisms including cell detoxi®cation (Dick et al., 1997) . In line with this limitation, no rigorous comparison of c-and v-Fos protein degradation inhibition by lactacystin could be conducted because, even though we observed no detectable stabilization of v-Fos FBR and v-Fos FBJ , cFos was inhibited to only 30 ± 50% in the 8 h long chases such as those conducted during this study. Despite their stabilization, v-Fos proteins are relatively short-lived, as compared to the bulk of cell proteins, and are sensitive to a proteolytic system(s) not operating on c-Fos. This illustrates that unstable proteins are not necessarily degraded by the proteasome. This notion is also supported by the recent ®nding of two T-cell receptor-associated ZAP-70 tyrosine kinase mutants aberrantly broken down via a yet to be identi®ed proteasome-independent pathway (Matsuda et al., 1999) . In the speci®c case of v-Fos proteins, the cell-penetrating protease inhibitors used in our study exclude a role for serine proteases such as TPPII, cysteine proteases such as calpains, caspases and SPase and lysosomal proteases. Development of reliable cell-free degradation assays will, therefore, be necessary for identi®cation of the cellular proteases responsible for v-Fos protein degradation. Finally, the ®nding that cellular and viral Fos proteins are degraded by dierent proteases in vivo indicates that highly related proteins can be broken down by fully distinct pathways. It is now essential to establish whether degradation of such proteins through dierent pathways exclusively concerns mutated or rearranged proteins or whether it also applies to the physiological degradation of groups of phylogenetically related cellular proteins, such as the members of certain multigene families or protein isoforms encoded by a same gene. It would, for example, be interesting to investigate whether the other members of the Fos family (Fra-1, Fra-2, FosB, DfosB) are all degraded by the proteasome.
We report here that neither stabilization, nor resistance to proteasomal degradation, nor sensitivity to another proteolytic system are due simply to the loss of the c-Fos C-terminal domain by v-Fos FBJ and vFos FBR . Rather, protein life spans are determined by a balance between opposing destabilizing and stabilizing mutations which are not the same in the two proteins. It is thus possible that both the mechanisms whereby the latter are stabilized and the proteases operating on them are dierent.
Whether resistance to the proteasome and sensitivity to another protease(s) can be uncoupled in the two viral proteins still remains to be determined. Identi®ca-tion of the protease(s) responsible for v-Fos FBJ and vFos FBR breakdown and availability of speci®c cellpenetrating inhibitors are, however, required to address this issue. How mutations in¯uence the conformation of these viral proteins is currently dicult to address because of our lack of knowledge of the Fos tertiary structure. It is however clear from our data that both viral proteins bear cryptic determinants for proteasomal degradation which are unrecognized in wild-type proteins. Whether these motifs are those which are naturally recognized within c-Fos remains to be established. Inversely, the c-FosDC48 mutant showed that c-Fos contains cryptic sites for (a) non-proteasomal proteolytic enzyme(s). It will thus be interesting to test whether the mutations in both viral proteins could have, through dierent mechanisms, the same ®nal eect, i.e. rendering accessible sites normally buried within the c-Fos structure to non-proteasomal proteolytic enzymes. Alternatively, it is possible that the mutations in v-Fos proteins induced conformational changes creating new recognition sites for nonproteasomal proteases.
Influence of myristoylation on v-Fos FBR degradation
In addition to their structural dierences, v-Fos FBJ and v-Fos FBR show very dierent biochemical and biological dierences. Thus, v-Fos FBJ is functionally and structurally very close to c-Fos (Piechaczyk and Blanchard, 1994) and both proteins are clearly discriminated only by their sensitivity to proteasomal degradation (this study) and the inability of the former to trans-repress the c-fos serum responsive element in transient transfection assays (Wilson and Treisman, 1988) . In contrast, v-Fos FBR manifests many biochemical and biological dierences primarily dependent upon myrOncogene c-Fos and v-Fos degradation C Acquaviva et al istoylation. Thus, myristoylation considerably reduces both transactivation activity via AP-1 DNA motifs (Kamata et al., 1991) and ability to repress c-fos gene promoter (Kamata and Holt, 1992 ) and confers to vFos FBR the ability to activate transcription without binding to DNA (Jotte et al., 1994) . It is also essential for the disruption of dierentiation-dependent expression of collagen III during adipocyte dierentiation (Abbott and Holt, 1997b) as well as the determination of the degree of dierentiation and tumorigenicity of malignant cells in transgenic mice (Jotte and Holt, 1996) and the inhibition of the cellular response to ionizing mutations (Abbott and Holt, 1997a) . In addition, we report that myristoylation is a crucial element both for regulating v-Fos FBR life span and for diverting it from proteasomal degradation towards another proteolytic system. The possible underlying mechanisms are multiple and still require clari®cation. It is, however, worth emphasizing that myristoylation per se is not inhibitory for proteasomal protein degradation since the Src tyrosine kinase is both stably (Resh, 1994) myristoylated and destroyed via the ubiquitin/proteasome pathway (Hakak and Martin, 1999; Harris et al., 1999) . A ®rst possible eect of myristoylation, described for the regulatory subunit of the PKA serine/threonine kinase (Yonemoto et al., 1993) , is stabilization of the protein structure most probably via intramolecular interactions with hydrophobic regions (Boutin, 1997) . The possibility that the myristyl group might impose a particular structural constraint to v-Fos FBR is all the more to be considered that comparison of the in vitro sensitivities of c-Fos, vFos FBJ and v-Fos FBR to calpains (the latter being proteases used as topological probes in crude structural assays since they recognize conformational determinants) demonstrated that the tertiary structure of vFos FBR is signi®cantly dierent from that of the two other proteins (Ste et al., 1997) . Alternatively, it can also be speculated that intermolecular interactions between myristyl groups and hydrophobic regions of other proteins favor and/or stabilize speci®c protein/ protein interactions and, thus, alter the partner protein repertoire of v-Fos FBR relative to that of c-Fos. A last possible eect is the control of intracellular protein localization. This is of particular relevance here because the targeting of a protein to a speci®c cell compartment has recently been shown to be important for breakdown of certain onco-suppressor proteins such as p53 (Boyd et al., 2000; Freedman and Levine, 1998; Geier et al., 1999; Tao and Levine, 1999) and the p21 inhibitor of cyclin-dependent kinases (Shea et al., 2000) . In contrast to other lipid modi®cations, myristoylation does not systematically result in protein association with membranes (Ahmed et al., 1993; Boutin, 1997; Olson et al., 1985) . For example, vFos FBR is essentially nuclear (Kamata et al., 1991; Roux et al., 1990) and the Gag-Akt fusion protein expressed by the AKT8 retrovirus is found nearly equally distributed between the plasma membrane, the nucleus and the cytosol (Ahmed et al., 1993) . However, in immuno¯uorescence assays, v-Fos FBR shows a punctuated pattern which is reversed to the characteristic diuse staining with nucleolar exclusion of c-Fos upon mutation of the myristoylation site (unpublished data).
Stabilization of viral Fos proteins with regard to the oncogenic potential of FBJ-MSV and FBR-MSV retroviruses
It is remarkable that fos genes expressed from FBJ-MSV and FBR-MSV retroviruses have gained the capability of constitutive expression through the alteration of multiple transcriptional and post-transcriptional regulations restricting c-fos expression to precise physiological conditions (Piechaczyk and Blanchard, 1994; Roux et al., 1990) . It is, however, puzzling that the escape of v-Fos proteins from proteasomal degradation is partially compensated by their sensitivity to another proteolytic system(s), which limits stabilization, and, thereby, accumulation to high levels. High levels of oncogene expression is often proapoptotic (Hanahan and Weinberg, 2000) and may account for the diculty in isolating stable cell lines expressing high levels of viral Fos proteins (C Acquaviva, M Piechaczyk, unpublished observations). It is thus tempting to speculate that the FBR-MSV and FBJ-MSV expression machineries have evolved to ensure controlled protein levels, corresponding to an optimal balance between pro-transformation and proapoptotic eects. Supporting this notion, transcription from viral LTRs is poor as compared to that of the activated c-fos promoter in run-on assays and viral FBR-MSV RNA is stabilized no more than 2 ± 3-fold as compared to the highly unstable c-fos mRNA (M Piechazyk, unpublished observations). (Curran et al., 1982) and FBR-1 , respectively. N-and/or C-terminally truncated Fos proteins were cloned after ampli®cation using 5'-and 3' oligonucleotides containing an AUG initiation codon or a stop codon, respectively, at the relevant amino acid position. G2A protein in which the second codon (GGA), coding for a glycine, was mutated to alanine (GCA).
Materials and methods
Expression plasmids
Cell transfection, pulse-chase experiments and protease inhibitors
Cos-7 cells were obtained from the American Type Culture Collection (Bethesda, MD, USA) and were grown in highglucose Dulbecco's modi®ed Eagle medium (Gibco/BRL) under standard conditions (Salvat et al., 1998) . Transient transfections were performed using the calcium phosphate coprecipitation procedure (Sambrook et al., 1989 ) using 5 ± 20 mg of expression vector per 2610 6 cells. Pulse-chase experiments were carried out 24 h later as in Treier et al. (1994) . For inhibition of cell proteolytic activities, MG 132 (5 mM; BioMol), calpain inhibitor II (50 mM, Boehringer), E64D (50 mM, Sigma), chloroquine (150 mM, Sigma) and AAF-CMK (50 mM, Sigma) were added to the medium at the beginning of the pulse and maintained during the entire period of the experiment. Z-VAD-FMK (100 mM, Sigma RBI) was added to the culture medium 1 h before the pulse. Conditions for the use of MG132, calpain inhibitor II, E64D and chloroquine were described elsewhere (Palombella et al., 1994; Salvat et al., 1998) . Z-VAD-FMK and AAF-CMK were shown to inhibit the activity of caspases and serine proteases, respectively, by 490 ± 95% under the experimental conditions used. The optimal concentration of Z-VAD-FMK was determined in separate experiments in which Cos-7 cells were induced to apoptose by 1 mM cycloheximide and 10 mg/ ml staurosporine and caspase activity was assessed by monitoring the cleavage of PARP with an anti-PARP antibody (Boehringer). For AAF-CMK, protease activity inhibition was assayed in extracts from drug-treated and nontreated Cos-7 cells using AAF-MCA as a¯uorogenic substrate (Osmulski and Gaczynska, 1998) .
Cell extracts and immunoprecipitations
Cell extracts were prepared as in Salvat et al. (1998) and immunoprecipitations were carried out using a standard protocol permitting quantitative protein pull down. Brie¯y, 300 mg of protein were incubated at 08C for 1 h with the relevant antibody in a ®nal volume of 500 ml adjusted with lysis buer. 15 ml of bovine serum albumin-preblocked Protein A-agarose (sc2002; Santa-Cruz Biotechnology) was added to each sample and incubation at 08C was continued for another 30 min under gentle agitation. Immunoprecipitates were pulled down by centrifugation at 600 g for 3 min at 08C, washed ®ve times with 500 ml of lysis buer, dissolved in 20 ml of electrophoresis sample buer (80 mM Tris-HCl pH 6.8, 10% glycerol, 4% SDS, 0.7 M b-mercaptoethanol, 300 mg/ml bromophenol blue) and boiled for 10 min. Proteins were electrophoresed through SDS 15% polyacrylamide gels (Harlow and Lane, 1999) . Gels were incubated in a sodium salicylate solution for¯uorography (Sambrook et al., 1989) , dried and exposed to Kodak X-OmatAR ®lms. For determination of protein half-lives (Doherty and Mayer, 1992) , the relative amounts of Fos proteins were quanti®ed by densitometer scanning of the autoradiographs exposed for the appropriate period of time followed by treatment of the data using the public domain NIH Image program available on the Internet at http://rsb.info.nig.gov/nih-image/. Several members of the Fos family display an electrophoretic mobility comparable to that of c-Fos and v-Fos FBJ and are recognized by many of the antibodies used for immoprecipitation of c-Fos. We thus tagged c-Fos/v-Fos FBJ chimera with a T7 phage epitope recognized by an anti-T7 monoclonal antibody (Novagen) generating no background in their molecular weight range to ensure immunoprecipitation of only transfected proteins. As a prerequisite to these experiments, we veri®ed that the T7 tag altered neither the half-life of c-Fos nor that of v-Fos FBJ in pulse-chase experiments using wild type (PM392 and PM463) and tagged (PM381 and PM314) expression plasmids (data not shown). Immunoprecipitations of these proteins were thus performed using 1 mg of the anti-T7 tag monoclonal antibody and bovine serum albumin-preblocked Protein A-agarose (sc2002; Santa-Cruz Biotechnology). In contrast, v-Fos FBR and derived mutants were not tagged because N-terminal addition of an epitope peptide would compromise protein myristoylation. These proteins were thus immunoprecipitated using 0.1 mg of the K25 anti-Fos family polyclonal antibody (sc253; SantaCruz Biotechnology) because, due to their dierent molecular weight, they could easily be distinguished from Fos or Fosrelated background bands.
